Zhongguancun Life Science Park Hosts 2023 Technology Platform Industry-Research Innovation Summit to Advance Biopharmaceutical Development

“The bioeconomy represents the fourth wave of human economic and social development, following the agricultural economy, industrial economy, and information economy.” Since the 18th National Congress of the Communist Party of China, China’s bioeconomy has achieved remarkable progress, with significantly enhanced innovation capabilities in the biological sector, major original breakthroughs in basic research, and life sciences emerging as a vibrant frontier in scientific research.

Seizing the historic opportunities presented by the new wave of technological revolution and industrial transformation, Zhongguancun Life Science Park, as a key pillar of Beijing’s “Three Cities and One District” master platform for building an international science and technology innovation hub, has invested in and attracted numerous biotechnology innovation platforms, thereby cultivating agglomeration advantages across the upstream and downstream segments of the industry chain.On March 24, 2023, Zhongguancun Life Science Park Co., Ltd. joined forces with multiple technology platforms to co-host the “2023 Zhongguancun Life Science Park Technology Platform Industry-Research Innovation Summit.”, focusing on core areas such as “AI-enabled new drug development,” “breakthroughs in undruggable targets,” “biopharmaceutical evaluation,” and “clinical biospecimen banking and utilization,” this initiative brings together industry leaders, investment experts, and leading/innovative entrepreneurs to pool diverse strengths and insights. By integrating the entire industry-academia-research-application chain, it aims to promote the establishment of a multi-level, broad-spectrum, functional, and open support system for novel innovation technology platforms.

This summit is organized byUnder the guidance of the Administrative Committee of Zhongguancun Life Science Park, Zhongguancun Life Science Park Company, Zhongguancun Life Science Park Incubator Company, and Changfa Zhan CompanyCombinedZhongguancun AI Drug R&D Platform, Beijing Clinical Data and Sample Resource Public Service Platform, Cryo-EM Platform, High-Resolution Mass Spectrometry Omics Platform, Biopharmaceutical Evaluation Platform, Integrated Biological Services CRO PlatformSix Core Biotechnology Innovation Platforms, by focusing on core aspects of pharmaceutical R&D such as basic research, target discovery, pilot-scale development, and drug analysis, we can further unlock the industry's potential, better foster the continuous growth of various new business models, and promote high-quality development in the field of life sciences and technology.

AsThe First Grand Event Jointly Hosted by Zhongguancun Life Science Park and Its Technical Platforms, this summit is themed1 Main Forum + 4 Thematic Sub-forumsin a format that maximizes the depth, breadth, cutting-edge nature, and richness of resources. The main forum will serve as a central platform for showcasing the insights of industry participants, where numerous industry leaders will engage in aOn Multiple Fields of Biotechnology, Including Laboratory Animals and Viral Infections“brainstorming.” The sub-forum focuses on“High-Quality Development and Sustainable Growth of Biobank Resources,” “AI-Enabled Innovative Drug R&D,” “Breaking Through Undruggable Targets,” and “Evaluation of Biologic Drugs”: Four Key DimensionsIn-Depth Analysis of Innovation and High-Quality Development Pathways and Strategies in Biopharmaceutical Technology.

CollectionOver 40 national academicians, heads of regulatory agencies, leading academics, executives of multinational pharmaceutical companies, directors of Grade A tertiary hospitals, and seasoned investorsand other prominent guests, coveringThe Six Major Circles of Government, Industry, Academia, Research, Healthcare, and Investment, converging new ideas, new technologies, and new business models, focusing on hot industry issues, jointly seeking truth and insights, and conducting comprehensive, high-level, high-quality, and forward-looking sharing and discussions.

2023 Zhongguancun Life Science Park Technology Platform R&D Innovation Summit

As China’s biopharmaceutical industry and its related support sectors gradually reach a turning point toward innovation, with steadily enhancing innovative capabilities and continuous breakthroughs in key biotechnologies, what opportunities will emerge for biopharmaceutical innovation?

This forum will bring together the core lineup of participants to discuss the prospects and future of the healthcare industry under the leadership of biotechnology.

Forum on the Collaborative and Innovative Development of “Industry-Academia-Research-Application” in Biobanking

In recent years, with the successive introduction of national laws and regulations on human genetic resources and supportive policies for the biopharmaceutical industry, a wave of biobank construction has swept across various institutions. However, establishing and maintaining high-quality biobank operations, addressing the issue of extensive sample storage coupled with low utilization and poor translational efficiency, and achieving sustainable development remain significant challenges for the industry.

At this forum, we will invite multiple biobank experts and industry leaders to jointly discuss the high-quality development and sustainable growth of biobanks, and to explore new models for collaborative innovation across “industry-academia-research-application” in the realm of biological sample resources.

Forum on AI-Empowered Innovative Drug R&D

In recent years, both artificial intelligence (AI) and biotechnology have achieved leapfrog developments in their respective fields. The advancement of deep learning has ushered in a new era for AI, resolving long-standing bottlenecks that have plagued academia, such as protein structure prediction. Meanwhile, the rapid progress of various omics technologies, exemplified by second-generation high-throughput sequencing and cryo-electron microscopy, has provided robust data generation capabilities, laying a solid foundation for algorithm training and optimization. Currently, AI is involved in every stage of biomedical development. With further technological advancements and breakthroughs, AI is poised to bring about disruptive changes to new drug research and development, holding broad prospects for the future.

This forum will invite AI companies, pharmaceutical companies, and investors to discuss AI-empowered innovative drug development.

Innovative Drugs and Innovative Technologies Forum 2023: Breaking Through Undruggable Targets

How can we leverage clinical sample analysis and proteomics to identify innovative targets with high disease relevance? How can we utilize high-resolution protein crystal structure determination platforms to gain insights into the druggability of these targets? How can we integrate drug design, drug screening, and multidimensional drug evaluation platforms to pioneer new avenues for the development of therapies against challenging-to-drug targets?

This forum will explore cutting-edge technologies and address the practical needs of the industry, providing insights into the latest technological advancements, druggable targets, new drugs, and molecular mechanisms.

Biopharmaceutical Evaluation Forum

With continuous breakthroughs in various types of biotech drugs and novel therapies, how to make optimal decisions at key stages during non-clinical and clinical evaluation of drugs has become a widespread concern.

This forum will introduce various new evaluation systems for non-clinical and early-stage clinical trials of drugs, as well as application cases of biotechnology drug evaluations.

Scan the QR Code to Attend